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 Biotin is an essential growth factor found in all living cells.  It functions as a 
cofactor for a group of coenzymes that catalyze transcarboxylation, decarboxylation, and 
carboxylation reactions. Acetyl CoA carboxylase catalyzes the first committed and 
regulated step in fatty acid synthesis in which malonyl CoA is the product. The biotin-
dependent enzyme is found in all animals, plants, and bacteria.  We studied the kinetic 
and structural aspects of acetyl CoA carboxylase, and in 1999 we reported the bioactivity 
and total synthesis of a unique first generation biotin-derived inhibitor of acetyl CoA 
carboxylase, 1(BP1).  Kinetic studies on the activity of E. coli biotin carboxylase yielded 
an inhibition constant of 8.4±1 mM. Since that time, we have improved the yield and 
purification of 1.  Currently, we are designing multisubstrate analogs which involve the 
attachment of adenosine moieties at the 1-N of biotin.  We reason that these compounds 
will have a greater affinity for acetyl CoA carboxylase.  In addition, we are synthesizing 
biotin derivatives for their study in three main areas: (1) understanding the mechanism of 
biotin carboxylase and acetyl CoA carboxylase for the development of new therapeutic 
agents, (2) screening for ribozyme activity to support the “RNA World” hypothesis, and 
(3) investigation of chiral cationic micelles for analytical separations. 
Chapter One  
Introduction 
1.1 Biotin-dependent Carboxylases 
Biotin, or vitamin H, is an essential component of all living cells.  It was first 
isolated as a growth factor for yeast in 1936 in its methyl ester form.1  The proposed 
structure for  (+)-biotin (Figure 1) was confirmed by the first total synthesis by Merck.2  
Structurally, the molecule consists of a bicyclic ring system whose mirror symmetry is 
broken by a valeric acid side chain.  The top ring of the bicyclic system is a ureido ring, 
and the bottom ring, containing sulfur, is a tetrahydrothiophene (or thiophane) ring.  











Figure 1: Structure of (+)-biotin 
 
The natural sources of biotin are the pancreas, liver, kidney, yeast, and egg yolk.  
Low levels of biotin in poultry and red meat cause a series of symptoms.  These 
deficiencies are corrected by using biotin as a feed additive. Biotin functions as a cofactor 
in carboxylation, decarboxylation, and transcarboxylation reactions related to 
biochemical processes such as glucogenesis and fatty acid synthesis.3 Because of its 
 1 
fundamental and commercial importance biotin has attracted the attention of both 
academic and industrial biologists and chemists. 
Acetyl CoA carboxylase (ACC) carries out the first committed and regulated step 
in fatty acid biosynthesis.  The biotin-containing enzyme catalyzes the ATP-dependent 
formation of malonyl CoA from acetyl CoA and bicarbonate.4  Acetyl CoA carboxylase 
is found in all animals, plants, and bacteria. Biotin-dependent enzymes, such as ACC, in 
general have three domains: the biotin carboxyl carrier protein, biotin carboxylase, and 
carboxytransferase (Figure 2). Depending on the organism, these components may occur 
as separate subunits. For example, pyruvate carboxylase has the biotinyl and 
transcarboxylase domains on one subunit and the biotin carboxylase on another, whereas 
in the carboxylases from some yeast, insects, vertebrates, and bacteria, such as 




















































Figure 2: The three domains of biotin-dependent enzymes. 
 2 
     Biotin-dependent carboxylases function by means of a two-step reaction 
sequence shown in Scheme 1.5  Biotin is covalently attached to the carboxyl carrier 
protein via an amide bond between the valeric acid side chain of biotin and the ∈ group 
of a lysine residue.  In the first half-reaction, Knowles describes the carboxylation of 
biotin whereby there is an ATP-driven attachment of carbon dioxide from bicarbonate at 
the 1’-N position of the biotin cyclic urea ring through the catalysis of biotin 
carboxylase.6 A carboxyphosphate intermediate is involved, and 1’-N-carboxybiotin is 
generated stepwise.  In the second half reaction, the activity of carboxytransferase  allows 
for the transfer of carbon dioxide from carboxybiotin to the acceptor, acetyl CoA, 
forming the product of fatty acid synthesis, malonyl CoA. 
 











Scheme 1: The two-step reaction used by all biotin-dependent enzymes. 
 
Since Knowles’s review in 1989,6 there have been several reviews on biotin-
dependent enzymes which describe the progress towards elucidating their mechanism of 
action.7,8,9  For several years, Strongin and Waldrop have collaboratively studied the 
structural and mechanistic aspects of the biotin carboxylase subunit of acetyl CoA 
carboxylase.  In 1999, they reported the total synthesis and bioactivity of the first biotin-
derived inhibitor of biotin carboxylase, compound 1, or BP1 (Figure 3).10,11  This thesis 
focuses on the efforts currently being made to improve the yield and purification of the 
 3 
BP1  analog as well as the synthesis of new biotin derivatives for their study in three 
main areas: (1) understanding the mechanism of biotin carboxylase for the development 
of new therapeutic agents, (2) screening for ribozyme activity to support the “RNA 























Figure 3: Compound 1 embodies a stable analog of the naturally occurring 
carboxyphosphate intermediate involved in biotin-mediated CO2. 
 
1.2 Background 
A number of proposed mechanisms for the carboxylation of biotin in reaction 1 
(Scheme 3) have been considered. These included the initial formation of a 
phosphobiotin intermediate which then reacts in a concerted reaction with bicarbonate to 
form carboxybiotin and Pi (Scheme 2a).  Another mechanism involved formation of 
carboxyphosphate.  Biotin is then directly carboxylated via a nucleophilic attack of the  
1-N of biotin on the carboxyl carbon.  Carboxyphosphate can also decarboxylate to form 
the strong electrophile CO2, which is then the carboxylating species (Scheme 2b). 
Knowles6 concluded that the most likely route to carboxybiotin was via a 
carboxyphosphate intermediate  from ATP and bicarbonate.  To date, however, there has 




































































Scheme 2: Mechanisms a and b are proposed mechanisms for the carboxylation of 
the 1’-N of biotin to form carboxybiotin.  Mechanism c suggests that a cysteine-
lysine base pair form the base and conjugate acid involved in the enolation of biotin. 
 
  
The favored route to carboxylation of biotin from carboxyphosphate involves 
initial proton abstraction from the 1’-N of biotin by an enzymic base, resulting in the 
formation of the enolate which can attack the carboxylating species. Attwood and 
coworkers9 proposed that a cysteine-lysine ion pair are involved in the conversion of 
biotin from the ureido to eneamine form (Scheme 2c). The lysine would deprotonate  
cysteine to form a thiolate anion, which would  remove the 1’-N proton from biotin.  The 
positively charged ∈-NH3+ of lysine stabilizes the enolate oxygen of biotin.  This would 
result in the enolate of biotin containing a very nucleophilic 1’-N, ready to attack the 
 5 
carboxylating species. On the contrary, a recent theoretical study by Grant15 has raised 
the possibility of there being concerted carboxylation and deprotonation of biotin in 
reaction 1 (Scheme 1). He also proposed a mechanistic role for sulfur on the thiophane 
ring of biotin.  Grant has calculated that a twisted conformation of the bicyclic ring 
structure can lead to orbital overlap between the sulfur and the ureido group, increasing 
the nucleophilic character of the 1’-N on biotin.   
Although many questions remain to be answered, many advances have been made 
relating to the study of the catalytic mechanism of biotin carboxylase as a result of the 
determination of the three–dimensional structure of biotin carboxylase by X-ray 
crystallography.15  High-resolution crystallographic structures of the biotin carboxylase 
subunit of acetyl CoA carboxylase co-crystallized with substrates would be an important 
breakthrough. 
 It is known from recent studies reported by Blanchard and Waldrop that biotin has 
a low affinity (Km =134 mM) for the enzyme acetyl CoA carboxylase in contrast to the 
Km values of 0.7 mM and 0.05 mM for bicarbonate and ATP, respectively.16  Therefore, 
one possible way to overcome low affinity of biotin for the enzyme is to synthesize a 
multisubstrate analog linking biotin to tighter binding substrates like bicarbonate and 
ATP as shown in Figure 4. The design and synthesis of 1 was the direct result of this 






























Figure 4: Substrates with varying affinities for acetyl CoA  carboxylase. 
 
The activity of biotin carboxylase was measured in the absence and presence of 
increasing amounts of 1.  As the concentration of the analog increased the initial velocity 
of biotin carboxylase from E.coli decreased.  Fitting the data to the equation for linear 
competitive inhibition by linear regression analysis yielded a slope inhibition constant of 
8.4±1mM.  While this is a modest degree of inhibition, placing a phosphonoacetic acid 
moiety at the 1-N of biotin allows BP1 to bind 10 times more tightly to the enzyme than 


















Figure 5: Proposed multisubstrate inhibitor(s) of biotin carboxylase. 
 
The new biotin derivatives we are currently synthesizing include multisubstrate 
inhibitors (Figure 5) that will incorporate AMP, ADP, and ATP, respectively.  The 
 7 
 8 
inhibition of these compounds will be compared to that of the patented BP1 analog.  We 
hypothesize that these derivatives will have a significantly lower inhibition constant than 


















There has been growing interest in our reaction intermediate analog BP1 since its 
total synthesis and inhibitory effect on biotin carboxylase were reported in 1999.10,11  In 
several collaborative efforts, we have studied BP1 as both an antiobesity and anti-HIV 
therapeutic agent.  In addition, compound 1 has been utilized as a substrate in the 
screening of ribozyme activity to support the “RNA World” hypothesis. 
The total synthesis of 1, (Scheme 3) described previously by Amspacher,10 begins 
with the protection of (+)-biotin as the corresponding ester in 95% yield via reaction with 
benzyl alcohol, DCC,  and catalytic amounts of HOBT and DMAP.  Biotin benzyl ester 2 
is reacted with chloroacetylchloride to furnish compound 3 in 98% yield.  Compound 3 
then undergoes an Arbuzov reaction with P(OEt)3 at 100°C to obtain phosphonate ester 4 
in 88% yield.  Hydrolysis of 4, promoted by TMSBr, provides the corresponding 
phosphonic acid in 72% yield.  Subsequent saponification of 5 with LiOH affords target 
compound 1 in 59% yield and an overall 22% yield. 
The synthesis of BP1 is straightforward and the yields of all intermediates are 
excellent.  The saponification step, however, is not as efficient when compared to the 
preceding four steps in the synthesis. I thus optimized the reaction conditions as well as 
the purification methods to improve the yield of the saponification reaction before 
















































































Scheme 3: The preparation of 1 from (+)-biotin. 
 
2.2 Improved Yield of Carboxyphosphate Reaction Intermediate Analog 
            We first attempted the cleavage of the benzyl ester on phosphonic acid 5 by more 
classical synthetic organic means, such as hydrogenation.  Although it is a known fact 
that sulfur poisons palladium catalysts, successful hydrogenation of sulfur-containing 
compounds has been previously reported.17   Compound 5 was reacted with 10% Pd/C  in 
THF  under H2 (50 psi) overnight; the target compound was not obtained. Further work 
may be necessary.  We meantime concluded reaction with LiOH followed by immediate 
neutralization and lyophilization of the reaction mixture were the optimum conditions. 
 10 
 The carboxphosphate reaction intermediate analog had only been synthesized 
previously on milligram scale.  In my efforts to scale up the saponification step, the pH 
sensitivity of BP1 as well as the polarity of starting material and final product became 
challenging issues.   The time required for the conversion of compound 5 to 1 is 
approximately 2 hrs ± 20 minutes. I discovered this 20-minute window made a significant 
difference in the yield of BP1 obtained.  Due to the polarity of the reactant and desired 
product, the exact time at which the reaction was complete was difficult to determine by 
thin layer chromatograghy (TLC). Stopping the reaction prematurely resulted in a polar 
mixture of starting material and product, which was seemingly impossible to separate.  
Even with polar solvent systems, such as 9:1 CHCl3: MeOH, 5% v/v Et3N, the retention 
times of the two compounds were indistinguishable. Removal of the phosphonic acid side 
chain at the C-N bond to afford biotin results when the reaction is allowed to exceed the 
time required for maximum conversion of phosphonic acid 5 to BP1. 
 I resolved these synthetic issues by carefully monitoring the saponification 
reaction by 1H NMR.  A small aliquot was taken from the reaction flask every 20 minutes 
and evaporated.  The concentrate was dissolved in D2O, and a 1H NMR was generated on 
a high-resolution spectrometer. I monitored the change in the chemical shift of the valeric 
acid α protons and stopped the reaction when the integral ratio of product to starting 
material was greatest.  Because the reaction proceeds towards the production of biotin as 
long as the reaction mixture is basic, the solution was immediately neutralized then 
lyophilized. In previous instances, the water was removed by evaporation in vacuo at 
high temperatures, contributing to partial decomposition of the desired product. By 
 11 
making these minor yet necessary changes, I increased the yield of BP1 from 59% to 
68%.   
2.3 HPLC Isolation of Carboxyphospate Reaction Intermediate Analog  
Target compound BP1 was formerly purified by recrystallization, which often 
affords a diminished yield of the desired compound due to the high temperatures 
employed.  Because BP1 is unstable at elevated temperatures, an alternative purification 
method was needed.  We anticipated isolation by HPLC coupled with the modified 
saponification experimental procedure would further increase the yield of reaction 
intermediate analog 1. 
The complexes of biotin with streptavidin and its structural homologue avidin are 
known to be the strongest ligand-protein complexes,18,19 with measured binding constants 
of 1.7×105 and 2.5×1013, respectively.18-21  The high affinity binding of these two systems 
has found many applications in affinity chromatograghy,22 and it is most commonly the 
technique of choice for the purification of biotin derivatives.  Contrarily, we decided to 
try another HPLC method for the isolation of compound 1-reverse phase 
chromatography.  As simple as the concept seemed, to our knowledge, isolation of biotin 
or biotinylated compounds had not been achieved without the employment of an affinity 
column.   
With the aid of my colleague Jorge Escobedo, reverse phase analysis of BP1, was 
performed with H2O and MeOH.  Composition of the eluent was isocratically changed 
from 100% H2O for 10 minutes to 100% MeOH over a 30-minute time period.  The UV 
detector was set at 205 nm and 240 nm.  The chromatogram generated (Figure 6) three 
peaks of interest, with retention times of 9.17, 11.83, and 41.0 minutes, respectively.  
 12 
These fractions were immediately lyophilized upon collection.  The fraction at 11.83 
minutes was confirmed by 1H NMR to be biotin. Therefore, we believed some degree of 
decomposition occurred.  Interestingly, the sample from which the fractions were isolated 
was allowed to sit at basic pH overnight before being injected. A proton NMR of the BP1 
standard from which the sample was prepared, however, contained all significant peaks, 
specifically the phosphonic acid α protons at ≈2.5 ppm.  In addition, the 31P NMR 
showed one single peak at approximately 15 ppm. This result supported our original 
hypothesis that the basicity of the solution causes removal of the phosphonic acid side 
chain. The NMR spectrum of the eluent at 9.17 minutes was also identified as a 
decomposed BP1 product, but to a lesser degree than 11.83 minute eluent. In contrast to 
spectrum of the fraction identified prove to biotin; the α protons were observed, but they 
were broad and diminished in size and integral ratio.  The peak at 41.0 minutes was not 
the desired product or any significant by-product, so no further characterization was 
performed. 
 
Figure 6: Chromatogram of BP1 aqueous solution (pH 8) allowed to sit overnight. 
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A series of experiments were performed to obtain conclusive evidence of whether 
the pH was affecting the separation of BP1 or merely the appearance of the 1H NMR 
spectrum generated.  Three BP1 aqueous solutions of varying pH’s were prepared.  The 
initial pH of each solution was approximately 9.  Using a 1.0M solution of HCl, the pH 
was adjusted to 5.5, 6.0, and neutral pH, respectively.  The samples were injected 
immediately upon preparation. Using the same gradient conditions described above, the 
best resolved chromatogram was obtained from analysis of the pH 6 solution.  This 
chromatogram is shown in Figure 7. For this particular case, the peaks of interest were at 
9.0, 10.5, and 16.8 minutes.  The 9.0 minute peak was determined to be insignificant, or a 
“ghost peak”.  The NMR sprectrum of the 10.5 minute fraction beared the closest 
resemblance to that of BP1, with the exception of the two characteristic α protons. The 
spectrum of the 16.8 minute peak overlayed with that of biotin with the exception of the 
amide protons, which have a chemical shift of approximately 6.5 ppm. Thus I could not 
yet conclude that BP1 was successfully isolated by HPLC.    
Figure 7: Chromatogram of BP1 aqueous solution (pH 6). 
 14 
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A 1H NMR of the standard BP1 solution (pH 8) was taken. The alpha protons 
were visible at the correct chemical shift and integrated properly.  The pH of the same 
sample was adjusted to 6; then another spectrum was generated.  The two peaks of 
interest were no longer present. In fact, the spectrum overlayed with that of the 10.5 
minute fraction isolated from the pH 6.0 solution (Figure 7).  The sample pH was then 
elevated back to ≈8.5, using saturated NaHCO3.  A final NMR was obtained, which was 
analogous to the spectra of the BP1 standard.  Hence, isolation of BP1 by reverse phase 
HPLC was accomplished. I concluded that the absence or presence of the α-protons in 




3.1 Effect of CABI  on Acetyl CoA Carboxylase Activity 
Obesity is characterized by an increase in the number and size of adipocytes.23 
During adipogenesis, the activities of several  lipogenic enzymes such as acetyl CoA 
carboxylase, fatty acid synthase, and ATP citrate lyase are increased.24  The elevated 
regulation of these enzymes suggests they could be targets for anti-obesity agents.  It has 
been demonstrated recently that mice treated with inhibitors of fatty acid synthase 
resulted in decreased food intake and weight loss.25  The hypothesis that acetyl-CoA 
carboxylase could be a target for anti-obesity agents was strengthened by  a recent study 
demonstrating that mice lacking the gene coding for the mitochondrial isoform of acetyl-
CoA carboxylase lost weight despite eating more food.26   
           A bisubstrate analog inhibitor of carboxyltransferase 6, the component of acetyl 
CoA carboxylase, which transfers carbon dioxide from biotin to acetyl CoA to form 
malonyl CoA, was synthesized by our collaborators Keith Levert and Grover Waldrop of 
Biological Sciences at Louisiana State University.27  Synthesis of this compound 
involved attack of the primary sulfur of coenzyme A to displace the chlorine on 
compound 3.  Since human acetyl CoA carboxylase is now a target for anti-obesity drugs, 
the question arose as to whether the bisubstrate analog could inhibit mammalian acetyl 
CoA carboxylase and in turn reduce lipid accumulation.  Unfortunately, the bisubstrate 
analog lacks the hydrophobic character needed to permeate a cell membrane. However, 
the chloroacetylated biotin derivative (CABI), or compound 3 is sufficiently hydrophobic 
to diffuse across the cell membrane. Although the mechanism is not yet fully understood, 
it is believed that CABI is able to permeate the cell membrane via passive diffusion, 
 16 
owing to its hydrophobicity.  Once inside the cell, 3 reacts with endogenous coenzyme A 
to form the bisubstrate analog, compound 6 (Figure 8), and thus inhibits acetyl CoA 






































Figure 8: Bisubstrate analog inhibitor of carboxyltransferase. 
 
          To aid in elucidating the mechanism by which CABI reacts with coenzyme A to 
inhibit acetyl CoA carboxylase activity, I have synthesized an adduct of CABI (Figure 9). 
Compound 7 is obtained in 75% yield via reacting biotin (0.25g, 0.75 mmol, 1 equiv), 
Et3N (0.32 mL, 2.24 mmol, 3 equiv), and acetyl chloride (0.081, 1.1 mmol, 1.5 equiv)  
under the same conditions employed to produce chloroacetylated compound 3.10 It will 
be used to determine if displacement of the chlorine by the primary sulfur of coenzyme A 



















          Our collaborators also performed a series of inhibition experiments to provide 
support for the CABI-CoA hypothesis.  To test the ability of CABI to reduce acetyl CoA 
carboxylase activity, Levert and Waldrop treated 3T3-L1 preadipocytes with a 10 µM 
solution of CABI in DMSO solution or a DMSO control for 4 hours.  The whole cell 
extracts were prepared and immediately used to measure acetyl CoA carboxylase activity 
by analytical reverse phase HPLC.  Treatment of preadipocytes with CABI resulted in a 
79% reduction of enzyme activity.28  As shown in Figure 10a, the specific activity for 
adipocytes treated with DMSO for  4 hours was 1.40 nmol malonyl CoA/min/mg protein. 
The activity significantly decreased to 0.30 nmol malonyl CoA/min/mg protein when 
3T3-L1 cells were treated with the 10 µM CABI of CABI in DMSO for the same period 
of time. 
          Professor Jackie Stephens, also of the department of Biological Sciences at 
Louisiana State University, analyzed the same cytosolic extracts for the expression of 
acetyl CoA carboxylase protein levels using streptavidin HRP (Figure 10b).  These 
results clearly demonstrate that the reduced activity of acetyl CoA carboxylase is not due 
to altered expression levels of the enzyme.  In other words, CABI treatment of 3T3-L1 
preadipocytes results in decreased acetyl CoA carboxylase activity, but not protein levels, 
in isolated cell extracts. 
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Figure 10: (A) The specific activity of preadipocytes treated with DMSO (control) or a 
10 µM solution of CABI in DMSO. (B) CABI shows no effect on protein levels of 
preadipoctytes as measured by streptavidin HRP. 
 
          The suggestion that CABI-CoA is formed from the reaction of CABI with 
endogenous coenzyme A was further strengthened by the fact that CABI had no effect on 
acetyl CoA activity in isolated cellular extracts.27  The bisubstrate analog 6, was indeed 
able to inhibit acetyl CoA carboxylase activity when added to isolated cellular extracts in 
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vitro.  The inhibition constant of CABI-CoA for bacterial acetyl CoA carboxylase was 
determined to be 23 µM.  Detection of CABI-CoA in extracts treated with CABI would 
provide conclusive evidence for the mechanism proposed.  Unfortunately, Levert’s 
attempts to isolate the bisubstrate analog have been unsuccessful using HPLC absorption 
optics.  Waldrop and coworkers have begun studies to detect compound 6 by more 
sensitive methods. 
3.2 Effect of CABI on Adipogenesis and Lipid Content 
          In addition to demonstrating that treatment of 3T3-L1 cells with CABI inhibits the 
activity of acetyl CoA carboxylase, our collaborators examined the effects of CABI on 
the adipogenesis of these cells.  Adipogenesis is coincident with expression of several 
key transcription factors.  To assess the adipocyte differntiation expression, Stephens 
analyzed PPARγ (Peroxisome Proliferator Activated Receptors), STAT1, and STAT5A 
(Signal Transducers and Activators of Transcription) by Western Blot Analysis.28  All 
three markers decreased in cells treated with 17µM and 8µM solutions of CABI in 
DMSO (Figure 11).  Untreated and control cultures showed no decrease in these markers.  
          STAT3 is a protein whose expression is not substantially regulated during 
differentiation.  As shown in Figure 11, the level of STAT3 was not affected by CABI at 
any concentration.  This observation was significant, because it suggests that CABI is not 
acting as a non-specific alkylating agent.  Moreover, the fact that the level of acetyl CoA 
carboxylase did not decrease with CABI treatment further indicates that CABI is not 






   










Figure 11: CABI blocks the induction of adipogenic transcription factors in a dose 
dependent manner.  Whole extracts were prepared one week after induction of 
differentiaton in the presence of various doses of CABI, as indicated at the top of the 
figure.  For each condition, the cells were cultured in the presence or absence of CABI or 
DMSO, and the cells were treated every 24 hours.  One hundred µg of each extract was 
separated by SDS-PAGE, transferred to nitrocellulose, and subjected to Western Blot 
Analysis. The molecular mass of each protein is indicated to the left of the blot in 
kilodaltons. 
   
 
          Exposure of differentiating adipocytes to 17µM or 8µM solutions of CABI in 
DMSO also blocked induction of lipid accumulation in a dose-dependent manner as 
measured by Oil red O staining (Figure 12).  It should be noted that the inhibition of 
CABI was reversible.  If the addition of compound 3 was not repeated every 24 hours, the 



















   
 
Figure 12: CABI inhibits lipid accumulation in differentiating 3T3-L1 cells.  Oil red 
O staining was performed on 3T3-L1 cells one week following the induction of 
differentiation.  Cells were induced to differentiate at 2 days post-confluence and CABI 
was replaced with DMEM.  The cells were treated every 24 hours with a fresh solution of 
CABI or DMSO.  Each plate was treated with the following concentrations of CABI: (A) 
0 µM, DMSO control; (B) 4 µM; (C) 8 µM; and (D) 17µM. 
 
          These results presented by Levert, Waldrop, and Stephens28 are the first 
demonstration of a link between a pharmalogical modulation of cytosolic acetyl CoA 
carboxylase and inhibition of adipogeneisis.  These studies support the gene knockout 
experiments in mice, which indicated that acetyl CoA carboxylase is a very promising 
target for antiobesity agents.26  The ability of CABI to prevent weight gain in mice fed 
high-fat diets is being investigated by biologists at Pennington Biomedical Research 
Center.  To aid in these experiments, I synthesized 40 grams of compound 3.  Currently, 
we are searching for alternative solvents and trying to synthesize a more soluble adduct 
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for these animal studies.  It is our desire to examine the effects of CABI  on other types of 
cells in which acetyl CoA carboxylase is up-regulated, such as in breast cancer cells.29 
3.3 The “RNA World” Hypothesis 
          For centuries, scientists have been wrestling with the challenge of formulating a 
plausible scenario for the origin and early evolution of life.  How did a self-replicating 
assembly of molecules emerge on early earth and give rise to cellular life?  One 
hypothesis is that early life was based on RNA.30, 31  That is, the first biocatalysts on 
Earth were not made of enzymes but were made of RNA  or a very similar polymer.   
          The appeal of the “RNA World” hypothesis is that catalytic RNA molecules, which 
could have served as their own genes, would have been much simpler to duplicate than 
proteins.  According to this theory, RNA promoted reactions required for life with the 
help of metals, pyridines, amino acids, and other small-molecule cofactors. As 
metabolism became more complex, RNA developed the ability to synthesize coded 
polypeptides that served as more sophisticated cofactors.  DNA later replaced RNA as the 
genetic polymer, and protein replaced RNA as the prominent biocatalyst.   
          In a collaborative effort with Professor Anne Grove and Steven Wilkinson of 
Biological Sciences at Louisiana State University, we are currently exploring another 
aspect of the “RNA World” hypothesis- CO2 fixation.  If the early atmosphere was 
abundant in carbon dioxide, as many biologists believe, then an RNA molecule(s) that 
can catalyze the carboxylation of biotin, the carrier of CO2, would have been essential for 
the existence of early life.   Typical metabolic reactions involve small molecules that are 
not attached to RNA.  Demonstrating that RNA can promote interesting reactions using a 
tethered substrate is difficult yet important in addressing the question of whether RNA 
 23 
can catalyze a reaction involving small compounds.  The ability to explore the repertoire 
of RNA catalysis dramatically improved with the development of randomization, 
selection, and amplification methods.32-34 Ribozymes with new or enhanced activities can 
now be isolated from large libraries of ribozyme variants,35-37 and entirely new ribozymes 
can be isolated from large pools of random-sequence molecules.38   
 














Figure 13: SELEX process in which BP1 was used for the selection of RNA molecules 
that demonstrate the greatest potential to catalyze the carboxylation of biotin. 
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          Compound 1, which mimics the carboxyphosphate intermediate in the 
carboxylation of biotin, is currently being used as a substrate to allow for the selection of 
RNA aptamers that likely possess the desired catalytic activity.  I synthesized 500 mg of 
BP1 using the optimized synthetic and purification conditions previously described.  The 
final product was submitted to our collaborators to be utilized to generate ribozymes that 
catalyze the carboxylation of biotin.   
          In a selection-amplification process known as SELEX (Systematic Evolution of 
Ligands by Exponential Enrichment), a library of RNA aptamers with affinity for BP1 
was isolated (Figure 13).   First, BP1 was coupled to an aganose column in aqueous 
solution.  During pre-selection, those RNA molecules possessing modest affinity for the 
tethered substrate were eluted from the column.  Next, the RNA aptamers that bound 
tightest to the BP1-aganose column were amplified.  This selection-amplification process 
was repeated until sequences with the desired activity dominated the pool.  The ultimate 
goal is to screen these RNA sequences for their catalytic capabilities. Grove and 
Wilkinson are diligently working to accomplish this task. If we are successful in 
discovering a ribozyme(s) that can catalyze the carboxylation of biotin, we will have 
extended the known catalytic capabilities of RNA to include CO2 fixation. 
3.4 Potential of BP1 As A Potent HIV Protease Inhibitor 
Human immunodeficiency virus (HIV) is the causative agent of AIDS (Acquired 
Immunodeficiency Syndrome).39  It encodes an aspartic acid protease, HIV PR, whose 
function is essential for proper viron assembly and maturation.  Inactivation of HIV 
protease by either mutation or chemical inhibition leads to the production of immature, 
non-infectious viral particles.  Thus inhibition of HIV PR is recognized as an important 
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therapeutic strategy for treatment of AIDS.40 Structural biochemical methods, nuclear 
magnetic resonance, and computational biochemistry are recent additions to the plethora 
of approaches used in the rational drug design and discovery process.  High-resolution 
crystal structures of HIV protease and HIV PR /inhibitor complexes have stimulated the 
synthesis of potent protease inhibitors.41     
 
(a) 
Figure 14: (a) Molecular model of BP1 (green) bound to the active site of HIV protease. 
(b) Position of BP1 in the flaps of the aspartic protease and its relation to Asp25/25’ and 
Ile50/50’             (Fig. con'd.) 




 Asp25’ Asp25 
(b) 
   
The experimental crystal structure of recombinant native HIV PR was first 
reported by scientists from Merck.42  While studies initially disagreed about certain 
details of the structure, they all confirmed that HIV protease is a homodimer and that the 
active site closely resembles that of other known aspartic proteases.41  Figure 14a shows 
BP1  bound to the active site of the aspartic acid protease.  Generation of this molecular 
model inspired us to explore the inhibitory effect of compound 1 on HIV PR.   
          Preliminary experiments were performed by Dr. Lui Marzilli, Chairman of the 
Department of Chemistry at Louisiana State University.  He reported minimal 
inactivation of HIV PR by compound 1.  Nevertheless, the reaction intermediate analog 
possesses several functional features that have been proven essential for the design of 
 27 
effective protease inhibitors: a cyclic urea moiety, symmetry or pseudosymmetry, and a 
biotin scaffold.  Hence, we believe, BP1 remains a strong anti-HIV drug candidate. 
The two halves of HIV protease are topologically related by an approximate 
intramolecular C2-axis.  Each monomer consists of 99 amino acid residues.  The active 
site triad (Asp25, Thr26, Gly27) is located in a loop whose structure is stabilized by a 
network of hydrogen bonds.  The flap, which consists of residues 45-55, is a β hairpin 
that covers the catalytic site and participates in the binding of inhibitors and substrates.  
Crystal structures indicate that interactions of molecules with Asp25/25’ and Ile50/50’ 
are particularly critical for high affinity and specificity for the viral protease. 








Figure 15: DMP323, a potent  symmetrical HIV protease inhibitor developed by DuPont 
Merck. 
 
In 1993, the DuPont Merck group succeeded in the development of a potent 
nonpeptide orally bioavailable HIV protease inhibitor, DMP32343 (Figure 15).  Design of 
this subnanomolar inhibitor was based on careful  inspection of the high-resolution of X-
ray structures available for HIV protease-inhibitor complexes.44  In all of these  
complexes, the backbone amide hydrogens of Ile 50 and 50’ in the flaps of the enzyme 
are hydrogen bonded to the carbonyl oxygen of the inhibitors through a tetra-coordinated 
H2O molecule.44  This H2O molecule is considered to play a critical role in closing the 
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“flaps” over the protease inhibitor and its presence has not been observed in mammalian 
aspartic proteases.  The rationale underlying the development of DMP323 was to displace 
the H2O molecule by the cyclic urea carbonyl oxygen.    Indeed the conserved H2O 
molecule was not seen in the HIV protease-DMP323 crystal structure.43  The structure of 
the protease/DMP323 complex reveals many stabilizing protein-ligand interactions.  It 
shows that the carbonyl oxygens of the catalytic aspartic residues, Asp 25,25’, and the 
diol oxygens of the inhibitor are positioned to form a network of hydrogen bonds. 
A magnified representation of the BP1-HIV PR complex (Figure 14b) shows the 
sites of interaction  between compound 1 and the flap residues of the aspartic protease.  
Although energy minimization studies have not been performed, I believe that the cyclic 
urea oxygen of BP1 is similarly positioned to perform the important role of accepting two 
hydrogen bonds from the Ile residues.  In fact, I propose that the modest inhibition 
reported by Marzilli is most attributed to this interaction. Understanding the relationship 
of BP1 to Asp 25 and 25’, which is less apparent from Figure 14b, is very likely the key 
to improving activity.   
 Initially, I concluded that the lack of activity of BP1 was directly related to the 
geometry of the compound.  However, recent studies revealed that the symmetry of the 
HIV protease dimer has guided the design of twofold and pseudosymmetric 
compounds.45  Kempf et al demonstrated that high oral bioavailability can be achieved 
with pseudosymmetric molecules.46  One such compound, A-7703 (Figure 16) possessed 
sufficient aqueous solubility for intravenous administration47 and was examined in 
clinical trials (unpublished results).  In the search for related inhibitors with improved 
bioavailability, A-80987 was produced.  It retained submicromolar antiviral activity.  
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More importantly, this potent inhibition was accompanied by significant oral 
bioavailability in three animal species and in humans.  Intense study of a series of A-
80987 analogues has now yielded valuable insight into the relationship of chemical 
structure to antiviral activity, aqueous solubility, and hepatic metabolism.  Application of 
these insights to compound design culminated in the discovery of ABT-538 (Figure 16), 























































Figure 16: Structures of pseudosymmetric bioavailable HIV protease inhibitors. 
 
 
 The X-ray structure of the streptavidin-biotin complex revealed the importance of 
the urea oxygen of (+)-biotin as a superior hydrogen-bond acceptor.47  The excellent 
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hydrogen bond accepting ability of urea was the reason Han and coworkers incorporated 
this functional group into their cyclic urea series of HIV PR inhibitors.43, 49  It later 
occurred to them that (+)-biotin, composed of two cis-fused five-membered rings with 
the important urea group, could be used as a scaffold for synthesizing anti-HIV 
compounds. Modeling suggested that the (+)-biotin derivatives can fit into the binding 
site of the protease, as demonstrated by the BP1-HIV PR complex. (Figure 14a).  In 
addition, the sulfur atom in (+)-biotin may form a weak hydrogen bond with the aspartic 
acid residues (25 and 25’).50  Han recently reported preliminary results of the synthesis 
and biological activities of biotin-derived HIV PR inhibitors.51  They succeeded in 
developing a new class of compounds with good transitions from Ki to antiviral IC90  
values.  The most potent inhibitor of this series, shown in Figure 21, has Ki of 0.5 µM 






X =Br, W = S, R = CH2OH
 




 In recent years, scientists have reported the design and synthesis of high-affinity 
bioavailable inhibitors that lack a C2 axis as well as potent anti-HIV compounds that 
possess a biotin scaffold.  Hence, I conclude that the modest activity exhibited by our 
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pseudosymmetric biotin-derived analog (1) is a matter of size rather than geometry or 
functionality.  I am convinced that extended substitution of the valeric acid and 
phosphonic acid side chains of BP1 will position the carbonyl oxygens closer to those of 
the flap residues Asp 25 and 25’. As a result, a stronger network of hydrogen bonds will 
be formed, which is essential to the stabilization of the inhibitor/protease complex. 
Chapter Four 
Biotin-Derived Chiral Cationic Polymeric Surfactant 
 
4.1 Introduction 
          The separation of enantiomeric mixtures into individual optical isomers is one of 
the most challenging issues in analytical chemistry.  Development of new methodologies 
for improved chiral separation is recognized as an important achievement by researchers 
in many areas of science, particularly, the pharmaceutical and agricultural industries.  In 
the former case, many drugs are chiral and therefore the design of and synthesis of these 
compounds often involve a racemic mixture rather than a pure form of the drug.  The 
problem is that one form of a racemic mixture may have a medicinal application while 
the other enantiomer may be very toxic, as in the case of thalidomide.52 These 
observations have resulted in the recent release of new FDA guidelines regulating the 
marketing of chiral drugs.  Such regulation has influenced the potential growth in the 
chirotechnology industry, specifically in the area of chiral drug separations.53   
 Early attempts to separate racemic mixtures into individual enantiomers employed 
naturally occurring chiral materials, such as wool54,55 and cellulose or other 
polysaccharides,56 in conjunction with standard separation methods.  These early 
strategies of the 1920’s provided some degree of success for separation of racemic 
mixtures.  However, isolations employing naturally occurring compounds are often 
complicated by their poor mechanical and chromatographic behavior. 
 Recent studies have demonstrated the use of chiral micelles as a viable alternative 
for achieving enantioselective separations.  These studies have been performed primarily 
by use of capillary electrophoresis,57,58 more specifically micellar electrokinetic 
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chromatography (MEKC).   In chiral recognition by this method, the micelles themselves 
can become the major site of interaction, or they can incorporate various chiral selectors 
which are added to the separation medium.  Even these systems are limited in their 
applications.  One major problem encountered with the use of normal micelles in MEKC 
is that the interactions of many analytes with these micelles are often too strong to allow 
adequate discrimination.  Warner and coworkers previously hypothesized that a 
polymeric surfactant will have stronger chiral recognition properties than conventional 
(non-polymerized) chiral micelles.   
 Professor Isiah Warner has dedicated the past five years of his career to offering 
unique possibilities for chiral separations.  During this time, the Warner research group 
has made significant advances and contributions to the scientific literature in this area of 
analytical chemistry.  Currently, the specific aim of his research is to examine the 
structural parameters that may contribute to the enhanced chiral recognition using 
polymeric surfactants rather than micelles.  The Warner and Strongin research groups 
will collaboratively assess the effect of polar head group type on the utility of the 











Figure 18: Structure of biotin-derived chiral cationic monomer. 
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The type of head group can provide drastic differences in the properties of the 
polymeric surfactant and thus in the elution window in the MEKC process.  To date, 
Warner et al. have only explored chiral head groups which are derivatives of amino acids.  
Previous experiments have shown that these anionic surfactants have particular 
appreciation for separation of cationic and neutral analytes.  However, there has been 
some difficulty with separation of anionic analytes.  It is believed that this is related to 
charge repulsion between the analyte and the highly anionic chiral polymeric surfactant.  
Therefore, a logical extention of the current research is to evaluate cationic polymeric 
surfactants.  To this end, we describe the synthesis of compound 8, a new chiral cationic 
biotion-derived monomer (Figure 18). 
4.2 Synthesis of Biotin-Derived Chiral Cationic Monomer 
          The synthesis of 8 (Scheme 4) begins with the transformation of (+)-biotin to the 
corresponding undecylenyl ester in 52% via stirring DMF (40 mL), biotin (1.0 g, 4.1 
mmol, 1 equiv), undecylenyl alcohol (1.02 mL, 5.11 mmol, 1.25 equiv), DMAP (0.05 g, 
0.41 mmol, 0.1 equiv), HOBT (0.06 g, 0.41 mmol, 0.1 equiv), and DCC (0.93 g, 4.5 
mmol, 1.1 equiv) at rt for 12 h.  Chloroacetylated compound 9 was obtained by two 
different synthetic methods.  The first procedure is based on Amspacher’s published 
procudure for highly regioselective acylation of biotin esters.10  Chloride 10 is afforded in 
59% yield by careful dropwise addition of Et3N (0.69 mL, 4.9 mmol, 3 equiv) and 
chloroacetylchloride (0.39 mL, 2.5 mmol, 1.5 equiv) in three portions (0.5 equiv every 12 
h) to a solution of biotin undecylenyl ester (0.65 g, 1.6 mmol, 1 equiv) in CH2Cl2  at –78 
°C; then the solution is warmed to rt. The alternative procedure was derived by Tanaji 
Talele, a post doc at Louisiana State University.  This method involves stirring of ester 9 
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(0.85 g, 2.14 mmol, 1 equiv) in chloroacetylchloride (8.5 mL, neat) at 65 °C for 3 h.   
Compound 10 is obtained in 24% yield.  This is a 50% decrease in the yield afforded by 
the original method.  Although we have not yet optimized these conditions, the advantage 
of the new method is a rapid conversion time of several hours as opposed to 2 days. 
Subsequently, allowing 10  (0.45g, 0.95 mmol, 1 equiv) to stir in pyridine (5 mL, neat) at 















































Scheme 4: Preparation of chiral cationic monomer from (+)-biotin. 
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Chapter Five  
Conclusion 
5.1 Future Work 
5.1.1 A New Synthetic Route to Carboxyphosphate Reaction Intermediate 1 
 In our efforts to improve the yield of the conversion of 5 to 1 (Scheme 3), it 
occurred to us that an alternative route to target compound 1 may be via a synthetic 
pathway which eliminates the saponification step completely. (Scheme 5). This method 
would reduce the number of steps required for the total transformation of (+)-biotin to 
BP1 from four to six.  Chloroacetylated compound 11 has been synthesized and 
characterized by 1H NMR and mass spectrometry. (+)-Biotin (1.00 g, 0.409 mmol, 1 
equiv) and chloroacetylchloride (10 mL, neat) were stirred at 65 °C for 5 hr to obtain 11 
in 14% yield.  The formation of phosphonate ester 12 has been confirmed by 1H NMR as 
well, however, further purification is required.  Currently, the specific aim of our research 
is to produce BP1 directly from the hydrolysis of unprotected compound 12.  Upon 
achieving this goal, the next task will be to fully characterize all intermediates and 
increase the efficiency of the modified synthesis. 
5.1.2 Multisubstrate and Transition State Analogs 
 The current work in this area focuses on attachment of adenosine moieties to the 
1’-N of (+)-biotin to form the structure(s) shown in Figure 5. Two strategies are currently 
being employed.  The first method involves coupling of CABI (3) to the thio-derivatives 
AMP, ADP, ATP to form the corresponding multisubstrate analog (Scheme 6).  The 
second procedure entails two reactions.  Compound 3 first undergoes an Arbuzov 
reaction to form a ethylchlorophosphonate adduct.58  This product is then reacted with the 
adenosine salt59,60 to form the desired multisubstrate analog61 (Scheme 7). Further work 
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on these schemes is required; therefore, yields have not been reported.  We are 
researching the most efficient synthetic and analytical conditions that will provide us with 























































































































































Scheme 7: Proposed synthesis of multisubstrate analogs which involves the  preparation 
of adenosine salts. 
 
 Work in progress also includes the design and synthesis of transitions state 
analogs to complement our reaction intermediate analog work (Figure 19). The 
development of these compounds may be applicable to our collaborative research project 
with Professor Anne Grove to support the “RNA World” hypothesis. Isolation of RNA 
aptamers based on their ability to bind transition-state analogs is a current approach to the 

































Figure 19:  Stuctures of proposed  transition state analogs. 
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 The development of analogs 19a and 19c is premature.The reaction conditions by 
which these compound will be synthesized are still being investigated. In contrast, an 
efficient route to transition state analog 19b has been derived (Scheme 8).  The 1H NMR 
spectrum of the crude reaction mixture indicated that the desired compound was 
produced. Because the compound was not pure, the percent yield was not determined. In 
addition, mass spectrometry generated a peak at 443.2 (calculated 442.55).  A mass peak 
of 459.4 was recorded as well.  The calculated mass of the oxidized by-product is 458.6 
g/mole.   The ratio of this peak to the former was approximately 9:1. Future work 
includes optimizing reaction conditions that will decrease the amount of side product 
formed.  for sulfonate transition-state analog 19b.  We will also investigate the best 





















   DBU
acetonitrile
19b  
Scheme 8: Preparation of transition state analog 19b from (+)-biotin. 
 
5.2 Conclusion 
In conclusion we have demonstrated the potential of reaction intermediate analog 1 
and and other biotin derivatives in several areas.  We have synthesized and studied BP1 
and analogs for inhibition of HIV protease and acetyl CoA carboxylase as well as began 
the screening for ribozyme activity.  We have synthesized CABI for in vitro adipogenesis 
and lipid content studies.  These results have led to scale up of the CABI synthesis for 
anitobesity studies in mice.  The synthesis of multsubstrate and trasition state analogs is 
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ongoing.  These compunds could serve as leads to a series of more potent inhibitors, 
based on biotin carboxylase’s role in fatty acid synthesis.  The transition state analags 
may be especially useful in the selection-amplification process employed in ribozyme 
screening.  We have also synthesized a chiral cationic monomer that will be utilized to 








6.1 Materials and Methods 
 Biotin was purchased from Bioworld.  All other reagents were purchased from 
Sigma or Aldrich.  All nonaqueous reactions were carried out under N2 or Ar in flame 
dried glassware.  CH2Cl2 and TMSBr were distilled over CaH2. Anhydrous DMF and 
pyridine were purchased from Aldrich. Analytical thin-layer chromatography (TLC) was 
performed using general purpose 60-Å silical gel on glass (Aldrich).  TLC plates were 
visualized with aqueous KMnO4 or I2.  Chromatography columns were packed with 
Kieselgel 60-Å silica gel 230-400 mesh (Sorbent Technologies).  Proton (1H) and carbon 
(13C) NMR spectra were generated on a Bruker ARX400, 400 MHz and a Bruker 
ARX250, 250 MHz spectrometer. IR spectra were recorded on a Nicolet 320 FT-IR 
spectrometer.  High-resolution mass spectrometry was provided by the Louisiana State 
University Mass Spectrometry Facility; spectra were recorded on a Finnigan MAT 900 
with a PATRIC detector. 
6.2 Experimental Procedures 
6.2.1 Purification of 5-(6,8-diaza-7-oxo-6-(2-phosphonoacetyl)-3-thiabicyclo[3.3.0] 
oct-2-yl) pentanoic acid 1  
 
          For reverse phase HPLC analysis a C-18 column (Dynamax 60 Å, C18 83-221-C) 
was used as a stationary phase.  The mobile phase was changed from 100% H2O to 100% 
MeOH over a 30 minute time period.  Flow rate was 5 mL/min.  MeOH was removed in 








 Benzyl ester 2 (0.25 g, 0.75 mmol) and Et3N (0.32 mL, 2.24 mmol) are added to 
10 mL of CH2Cl2.  Acetylchloride (0.081 mL, 1.1 mmol) is added in three portions. The 
mixture is stirred and brought to –78 °C; then acetylchloride (0.027 mL, 0.37 mmol) is 
added.  The mixture is stirred for 12 hours and allowed to warm to room temperature.  
This series of steps is repeated 2 more times.  The reaction mixture is filtered and the 
filtrate is evaporated in vacuo. Then the resultant thick brownish oil is dissolved in 
CH2Cl2, absorbed on to silica, and purified by column chromatography.  A solution of 
4% MeOH, 48% hexane, and 48% EtOAc is used as the mobile phase to afford a 
yellowish oil (0.21 g, 75%).  1H NMR (DMSO-d6) δ 7.90 (s, 1H), 7.35 (s, 5H), 5.08 (s, 
2H), 4.75 (m, 1H), 4.12 (m, 1H), 3.29 (m, 1H), 2.95-2.85 (m, 2H), 2.49 (t, J = 7.2 Hz, 
2H), 2.34 (s, 3H), 1.72-1.25 (m, 6H); 13C NMR (DMSO-d6) δ 173.58, 170.22, 157.04, 
137.14, 129.30, 128.85, 66.20, 61.85, 57.95, 55.58, 34.48, 34.11, 28.84, 25.26, 24.32; IR 
(thin film) 3252, 3131, 2936, 1684, 1375, 1251, 755, 699, 632; HRMS: found 377.40, 
calculated 376.47. 
6.2.3 Undec-10-enyl 5-[3aS, 4S, 6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl]pentanoate 9 
 
 (+)-Biotin (1.00 g, 4.09 mmol), undecylenyl alcohol (1.02 mL, 5.11 mmol), 
DMAP (0.05g, 0.409 mmol), and HOBT (0.055 g, 0.409 mmol) are added to a 40 mL of 
DMF in a 250 mL 3-neck round bottom flask.  The mixture is mildly heated while 
stirring until a homogeneous solution of reagents is achieved.  DCC (0.93 g, 4.5 mmol) is 
added; then the reaction mixture is allowed to stir at room temperature for 12 hours.  The 
reaction mixture is filtered and the filtrate was concentrated in vacuo.  The resultant solid 
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is dissolved in CH2Cl2 and extracted three times with H2O.  The organic layer is dried 
over MgSO4 and filtered.  The organic filtrate is concentrated and the pale yellow solid is 
purified by flash chromatography with 5% MeOH, 95% EtOAc to obtain a white solid 9 
in 52% yield.  1H NMR (DMSO-d6) δ 6.42 (s, 1H), 6.35 (s, 1H), 5.74 (m,1H), 5.02-4.91 
(m, 2H), 4.35 (m, 1H), 4.11 (m, 1H), 3.98 (t, J = 7.3 Hz, 2H), 2.01 (m 2H), 2.87-2.51 (m, 
2H), 1.51-1.25 (m, 20H); 13C NMR (DMSO-d6) δ 173.75, 163.56, 139.70, 115.52, 76.09, 
64.54, 61.90, 60.04, 56.23, 34.05, 29.75, 29.48, 29.35, 29.13, 28.99, 28.88, 26.24, 25.43; 
IR (KBr) 3257, 2918, 2815, 1710, 1731, 1473, 1422, 1267, 1178, 901, 731, 658; HRMS: 
found 397.32, calculated 396.59 
 
Figure 20: 1H NMR spectrum of 7. 
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Figure 21: Carbon 13 spectrum of 7. 
Figure 22: 1H NMR spectrum of 9. 
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Figure 23: COSY NMR  spectrum of 9. 
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Figure 24: Carbon 13 NMR spectrum of 9. 
 
6.2.4 Undec-10-enyl 5-[3aS,4S,6aR)-1-(chloroacetyl)-2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl]pentanoate 10  
 
 Undecylenyl ester 9 (0.65g, 1.64 mmol) and Et3N (0.69 mL, 4.92 mmol) are 
added to 20 mL of CH2Cl2.  Chloroacetylchloride (0.39 mL, 2.46 mmol) is added in three 
portions.  The reaction mixture is stirred at –78 °C and chloroacetylchloride (0.065 mL, 
0.82 mmol) is added to the flask.  The solution is allowed to stir at room temperature for 
12 hours.  This sequence of steps is repeated two more times.  The crude reaction mixture 
was evaporated in vacuo and the resultant light brown oil is dissolved in CH2Cl2 and 
purified by flash chromatography with 4% MeOH, 48% EtOAc, 48% hexane.  A yellow 
oil is furnished in 59% yield.  Via an alternative method, compound 9 (0.85 g, 2.14 
mmol) is added to chloroacetylchloride (0.85 mL, neat).  The reaction mixture is allowed 
to stir at 65 °C for 3 hours.  The solution is allowed to warn to room temperature then 
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diluted with CH2Cl2.  While stirring, H2O was carefully added over 3 minutes. Then the 
organic phase is washed twice more with H2O and once with concentrated NaHCO3.  The 
CH2Cl2 layer is dried over MgSO4 then filtered.  The filtrate is evaporated in vacuo.  The 
resultant yellow oil is dissolved in 4% MeOH 48% hexane 48% EtOAc and purified by 
column chromatography with the same solvent system.  A yellow solid is afforded in 24 
% yield.  1H NMR (DMSO-d6) δ 8.09 (s, 1H), 5.77 (m ,1H), 5.01-4.90 (m, 2H), 4.79 (m, 
3H), 4.18 (m, 1H), 3.98 (t, J = 6.5 Hz, 2H), 3.13 (m, 1H), 3.03-2.87 (m, 2H), 2.28 (t, J = 
7.3 Hz, 2H), 2.01 (m, 2H), 1.68-1.24 (m, 20H); 13C NMR (DMSO-d6) δ 173.72, 166.32, 
156.65, 139.69, 115.53, 64.56, 62.21, 58.87, 55.46, 44.84, 34.05, 29.76, 29.65, 29.49, 
29.36, 29.13, 29.01, 28.85, 26.24, 25.31; IR (KBr) 3346, 2927, 2855, 1740, 1700, 1394, 
1234, 1100, 795; HRMS: found 473.32, calculated 473.07. 
 
Figure 25: 1H NMR spectrum of 10. 
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Figure 27: 1H NMR spectrum of 8. 
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 Chloracetylated compound 10 (0.45 g, 0.95 mmol) is allowed to stir in pyridine (5 
mL, neat) at room temperature for 12 hours.  The reaction mixture is concentrated in 
vacuo.  The resultant yellow oil was dissolved in CH2Cl2 and purified by column 
chromatography in 10% MeOH 90% CH2Cl2 to afford a yellow solid in 41% yield.  1H 
NMR (DMSO-d6) δ 9.0 (m, 2H), 8.75 (m, 1H), 8.43 (s, 1H), 8.31 (m, 2H), 6.0 (m, 2H), 
5.80 (m, 1H), 5.01-4.83 (m, 2H), 4.78 (m, 1H), 4.30 (m, 1H), 3.99 (t, J = 6.5 Hz, 2H), 
3.15 (m, 1H), 2.98-2.87 (m, 2H), 2.30 (t, J = 7.3 Hz, 2H), 1.95 (m, 2H), 1.64-1.25 (m, 
20H); 13C NMR (DMSO-d6) δ 173.73, 165.93, 156.74, 147.40, 139.68, 128.30, 115.52, 
76.12, 64.56, 62.00, 59.48, 55.45, 34.05, 29.74, 29.64, 29.49, 29.36, 29.13, 29.00, 26.24, 
25.31; IR (KBr) 3206, 3078, 2922, 2854, 1743, 175, 1653, 1634, 1327, 1254, 1187, 851, 
768, 690; HRMS: found 516.41, calculated 516.40. 
 50 
6.2.6 5-[3aS,4S,6aR)-1-(chloroacetyl)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl]pentanoic acid 11 
 
 (+)-Biotin (1.00 g, 0.409 mmol) was added to chloroacetylchloride (10 mL, neat)  
in a 50 mL round bottom flask.  The reaction mixture was allowed to stir at 65 °C for 5 
hours.  The chloraocetylchloride was removed by vacuum distillation.  The resultant 
milky suspension was dissolved in CH2Cl2 and washed three times with H2O and once 
with saturated NaHCO3.  The organic layer was dried over MgSO4.  The solid was 
purified by column chromatography using 10% MeOH 90% EtOAc mobile phase to 
obtain a white solid in 15% yield.  1H NMR (DMSO-d6) δ 8.10 (s, 1H), 4.79 (m, 3H), 
4.31 (m, 1H), 3.32 (m, 1H), 3.04-2.79 (m, 2H), 2.18 (t, J = 7.3 Hz, 2H), 1.78-1.23 (m, 
6H); HRMS: found 321.3, calculated 320.79 
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